ClinicalTrials.gg
RecruitingNCT07462247Updated Mar 12, 2026

Establishment of Image Database for Early Upper Gastrointestinal Cancer, Precancerous Lesions, and Precancerous Conditions

An observational study in Upper Gastrointestinal Cancer, Upper Gastrointestinal Precancerous Lesions and Upper Gastrointestinal Precancerous Conditions, sponsored by Changhai Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Changhai Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies in Gastrointestinal Neoplasms with a site in China — 44 open to participants now, 51 under way, 6 of them phase 3. Gastrointestinal Neoplasms · China.

Planned enrollment
9th of 22
500 · median 500
Started
2026
with 10 others
Observational
22 of 110
7 open now
Primary completion
2030-12
later than 49 of 50 live
Registered
101st of 110
by date

Among the 110 studies in Gastrointestinal Neoplasms with a site in China, this one is the 9th largest by planned enrollment of the 22 observational ones that give a count, is one of 11 that started in 2026, is one of 22 observational ones, reaches primary completion later than 49 of the 50 other live ones, and was the 101st registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

44 of the 110 studies in Gastrointestinal Neoplasms with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Gastrointestinal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The study is designed to collect magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, CT images, and histopathology results to establish a database for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions.

Read the detailed description

Images of MCE for UGIC are scarce, limiting the development of corresponding AI diagnostic model. We aim to create an image database with MCE images, EGD images, CT images, and histopathology results, in patients treated by ESD for early upper gastrointestinal cancer, or biopsy for precancerous lesions, and precancerous conditions, so as to facilitate image-based deep learning studies.

03

Conditions studied

  • Upper Gastrointestinal Cancer
  • Upper Gastrointestinal Precancerous Lesions
  • Upper Gastrointestinal Precancerous Conditions

Keywords

  • image database
  • upper gastrointestinal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Tertiary Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged ≥ 18 years
  2. Patients with early upper gastrointestinal cancer referred for endoscopic submucosal dissection (ESD), or patients with upper gastrointestinal precancerous lesions or precancerous conditions referred for by esophagogastroduodenoscopy (EGD)
  3. Participants who are willing and able to participate in this study, complete all required examinations and follow-up visits, and who have provided written

Exclusion criteria

Exclusion Criteria:

  1. Patients who are not eligible for surgery or who refuse any abdominal surgery in case of capsule retention and endoscopic retrieval failure
  2. Patients with cardiac pacemaker or other implanted electromedical devices which could interfere with magnetic resonance
  3. Suspected or known intestinal stenosis or other known risk factors for capsule retention
  4. Patients with dysphagia
  5. Pregnancy
  6. Allergy to polymeric materials, latex, simethicone, or pronase
  7. Patients plan to undergo magnetic resonance imaging examination before excretion of the capsule
  8. Patients with any condition that precludes compliance with the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testmagnetically-controlled capsule endoscopy, esophagogastroduodenoscopy, CT scan

    Magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions

  • ProcedureESD, biopsy

    ESD or biopsy for histopathology results

06

What researchers measure

Primary outcomes

  1. Magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images

    Time frame: Prior to ESD or biopsy

  2. Histopathology results

    Time frame: During ESD or biopsy

07

Study locations

1 of 1 sites recruiting
  • Changhai Hosptial
    Shanghai, 200433, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2030, 57 months after the start.

Of 79 non-industry observational studies under Gastrointestinal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 14. This study's planned 57 months is above that.

Counting every sponsor, half of 88 studies reached it within 43 months; a quarter within 16 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 10, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462247
Lead sponsor
Changhai Hospital
Responsible party
Jun Pan (Principal Investigator, Changhai Hospital) — Principal investigator
First posted
Mar 10, 2026
Start date
Mar 11, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Mar 12, 2026

Study contacts

Jun Pan, MD
Contact
panjun059@163.com
+86-13764598567
Jun Pan, MD
principal investigator · Changhai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion